Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality

Author： Lernia Vito Di Ricci Cinzia

Publisher： Informa Healthcare

ISSN： 1471-1753

Source： Journal of Dermatological Treatment, Vol.22, Iss.4, 2011-08, pp. : 229-232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Severe Exacerbation of Psoriatic Arthritis During Treatment with Efalizumab. A Case Report

By Bang Bo Gniadecki Robert

Acta Dermato-Venereologica, Vol. 86, Iss. 5, 2006-09 ,pp. : 456-457

Medical Journals Limited

Access to resources Recommend Favorite

Treatment of Recalcitrant Dermatomyositis with Efalizumab

By Huber Andrea Gaffal Evelyn Bieber Thomas Tüting Thomas Wenzel Joerg

Acta Dermato-Venereologica, Vol. 86, Iss. 3, 2006-05 ,pp. : 254-255

Medical Journals Limited

Access to resources Recommend Favorite

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

By Pincelli Carlo

Archives of Dermatological Research, Vol. 298, Iss. 7, 2006-12 ,pp. : 329-338

Springer Publishing Company

Access to resources Recommend Favorite

Dose-creep of Infliximab During Psoriasis Treatment: An Observational Study

By Mehren Christine R. Gniadecki Robert

Acta Dermato-Venereologica, Vol. 92, Iss. 4, 2012-07 ,pp. : 355-357

Medical Journals Limited

Access to resources Recommend Favorite

Palmoplantar Pustular Psoriasis: Successful Therapy with Efalizumab after Non-response to Infliximab

By Wozel Gottfried Vitéz Lilla

Acta Dermato-Venereologica, Vol. 88, Iss. 2, 2008-01 ,pp. : 169-170

Medical Journals Limited

Access to resources Recommend Favorite